Paper Details

  1. Home
  2. Paper Details

Erythema nodosum-like lesions during BRAF inhibitor therapy: Report on 16 new cases and review of the literature.

Author: BerkingC, GutzmerR, HasselJ C, HoellerC, KählerK C, LoquaiC, MössnerR, RichtigE, UgurelS, ZimmerL

ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study investigated cases of erythema nodosum-like inflammatory skin lesions associated with BRAF inhibitor therapy for BRAF-mutated melanoma. 16 patients developed these lesions, 14 receiving vemurafenib and 2 receiving dabrafenib plus trametinib. Histopathology revealed panniculitis or vasculitis in 5 cases. Symptomatic management was sufficient in most cases, but 3 patients discontinued treatment due to severe symptoms.
Paper Details　
Original Abstract of the Article :
IMPORTANCE: BRAF inhibitors have been licensed for the therapy of BRAF-mutated melanoma. Recently, inflammatory skin lesions clinically resembling erythema nodosum have been reported as therapy side-effects that may lead to treatment discontinuation. OBJECTIVE: To identify and characterize cases wi...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/jdv.13039

データ提供：米国国立医学図書館（NLM）

Erythema Nodosum-like Lesions: A Potential Side Effect of BRAF Inhibitor Therapy

BRAF inhibitors have revolutionized the treatment of BRAF-mutated melanoma, offering a targeted approach to fighting this aggressive cancer. This research explores a potential side effect of BRAF inhibitor therapy: erythema nodosum-like inflammatory skin lesions. The study, based on a retrospective chart review and literature review, examines the characteristics and management of this side effect.

Navigating the Side Effects of BRAF Inhibitor Therapy

The research reveals that erythema nodosum-like lesions, characterized by red, tender bumps on the skin, are a potential side effect of BRAF inhibitor therapy. This finding is like discovering a hidden obstacle on a desert trail; it’s important to be aware of these potential side effects and to manage them effectively.

A Multifaceted Approach to Managing Skin Reactions

The study highlights the need for a multifaceted approach to managing erythema nodosum-like lesions, including symptomatic treatment and, in some cases, interruption of BRAF inhibitor therapy. This underscores the importance of careful monitoring and personalized care in managing potential side effects of targeted therapies.

Dr.Camel's Conclusion

The desert of cancer treatment can be a treacherous landscape, and targeted therapies like BRAF inhibitors, while offering hope, can sometimes come with unexpected side effects. This research serves as a reminder of the importance of careful observation and a multi-faceted approach to managing potential side effects, ensuring the safety and well-being of patients navigating the complex terrain of cancer treatment.

Date :
  1. Date Completed 2016-05-26
  2. Date Revised 2022-04-19
Further Info :

Pubmed ID

25752368

DOI: Digital Object Identifier

10.1111/jdv.13039

Related Literature

Article Analysis
・Side Effects of trametinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.